This disappointing result is in line with previous observations on the lack of efficacy of other anti-angiogenic drugs in AML, such as the VEGF antibody bevacizumab when given alone [23] or in combination [24]. The gene discussed is VEGFA; the disease is acute myeloid leukemia.